
    
      The sunitinib non-interventional (NI) study is a real world observational study which
      represents the usual and customary treatment of patients and being proposed to collect data
      systematically and to assess the safety and efficacy in Chinese patients with progressive,
      unresectable, advanced or metastatic well-differentiated, pancreatic neuroendocrine tumors.It
      is designed and conducted to meet CFDA post-marketing commitments. non-probability sample
    
  